CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's...
Hence then, the article about kelun biotech presents pivotal phase ii data for lunbotinib fumarate a400 ep0031 in ret fusion positive nsclc at 2026 asco was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO )
Also on site :
- Airwallex Challenges Legacy Software With New Billing Solution .. PYMNTS.com
- ‘The Birds’ Limited Series Starring Sarah Snook Hits TV Marketplace; New Take On Hitchcock’s Classic Comes From Tom Spezialy, David Heyman & UIS
- Not the finest hour: BBC slammed over Churchill and Gandhi deepfakes (VIDEO)